Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Glaxo Patent Suit


International Outlook: Global Wrapup

GLAXO PATENT SUIT

A case crucial to the future of the big British drugmaker Glaxo is beginning in North Carolina. Glaxo is suing to stop Canadian generics maker Novopharm Ltd. from introducing a knockoff of Glaxo's antiulcer drug Zantac to the U.S. in 1995. Novopharm contends that Glaxo should lose patent protection then, not in 2002 as scheduled. If Glaxo loses, generics could grab the lion's share of the market--devastating Glaxo, which gets 60% of its profits from Zantac.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus